CLINICAL TRIALS OF ANTIFUNGAL THERAPIES

抗真菌疗法的临床试验

• 批准号: 6333343
• 负责人: William E. Dismukes
• 金额: $ 149.57万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-10-21 至 2000-10-20
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6333343
• 关键词: Aspergillus; Candida; Coccidioides immitis; Cryptococcus; HIV infections; Histoplasma; antifungal agents; biomedical resource; clinical research; human subject; human therapy evaluation; microorganism disease chemotherapy; mycosis; opportunistic infections

The objective of this contract is to provide a clinical trial collaborative group accessing the appropriate at-risk populations and providing the expertise to construct and conduct controlled clinical trials addressed the key management problems in serious fungal diseases. The group will be coordinated and evaluated by a coordinating institution. It is expected that the group will: 1) Formulates scientific agenda prioritized according to public health needs for approval by the NIAID; 2) Secure industrial support for patient care and related costs to enable the proposed trials to run to completion; 3) Provide administrative data management and statistical support for development, implementation and analysis of the trials; 4) Provide site monitoring and data and safety quality assurance; and 5) Assess and report progress and results, including summaries and analyses as required by an independent Data and Safety Monitoring Board and for the safety of all studies.

该合同的目的是提供临床试验 协作小组访问适当的处于危险的人群和 提供专业知识来构建和进行控制的临床 试验解决了严重真菌疾病的主要管理问题。 该小组将通过协调机构进行协调和评估。 预计该小组将： 1）根据公共卫生的优先级制定科学议程 NIAID批准的需求； 2）确保患者护理的工业支持和相关费用以启用 拟议的试验要完成； 3）为行政数据管理和统计支持 试验的开发，实施和分析； 4）提供现场监控和数据和安全质量保证；和 5）评估和报告进度和结果，包括摘要和 独立数据和安全监控委员会的要求进行分析 以及所有研究的安全。

项目成果

Surveillance of cryptococcosis in Alabama, 1992-1994.

阿拉巴马州隐球菌病监测，1992-1994 年。

• DOI: 10.1016/s1047-2797(97)00234-2
• 发表时间: 1998
• 期刊: Annals of epidemiology
• 影响因子: 5.6
• 作者: Thomas,CJ;Lee,JY;Conn,LA;Bradley,ME;Gillespie,RW;Dill,SR;Pinner,RW;Pappas,PG
• 通讯作者: Pappas,PG

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.

• DOI: 10.1056/nejm200201243460403
• 发表时间: 2002-01-24
• 期刊: NEW ENGLAND JOURNAL OF MEDICINE
• 影响因子: 158.5
• 作者: Walsh, TJ;Pappas, P;Lee, J
• 通讯作者: Lee, J

Triazole therapy for mucocutaneous candidiasis in HIV-infected patients.

三唑疗法治疗艾滋病毒感染者皮肤粘膜念珠菌病。

• DOI: 10.1016/s1055-3290(98)80031-9
• 发表时间: 1998
• 期刊: The Journal of the Association of Nurses in AIDS Care : JANAC
• 作者: Thomas,CJ

Protection against lethal murine coccidioidomycosis by a soluble vaccine from spherules.

通过可溶性小球疫苗预防致命的鼠球孢子菌病。

• DOI: 10.1128/iai.66.5.2342-2345.1998
• 发表时间: 1998
• 期刊: Infection and immunity
• 影响因子: 3.1
• 作者: Zimmermann,CR;Johnson,SM;Martens,GW;White,AG;Zimmer,BL;Pappagianis,D
• 通讯作者: Pappagianis,D

Treatment of blastomycosis with higher doses of fluconazole. The National Institute of Allergy and Infectious Diseases Mycoses Study Group.

用较高剂量的氟康唑治疗芽生菌病。

• DOI: 10.1086/514539
• 发表时间: 1997
• 期刊: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
• 作者: Pappas,PG;Bradsher,RW;Kauffman,CA;Cloud,GA;Thomas,CJ;CampbellJr,GD;Chapman,SW;Newman,C;Dismukes,WE
• 通讯作者: Dismukes,WE